About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Elavl1tm1Thla
targeted mutation 1, Timothy Hla
MGI:4414853
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Elavl1tm1Thla/Elavl1tm1Thla
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+ 		involves: 129 MGI:4414940


Genotype
MGI:4414940
cn1
Allelic
Composition		 Elavl1tm1Thla/Elavl1tm1Thla
Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+
Genetic
Background		 involves: 129
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Elavl1tm1Thla mutation (1 available); any Elavl1 mutation (43 available)
Gt(ROSA)26Sortm1(cre/ERT2)Alj mutation (0 available); any Gt(ROSA)26Sor mutation (993 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype

Cachexic phenotype of Elavl1tm1Thla/Elavl1tm1Thla Gt(ROSA)26Sortm1(cre/ERT2)Alj/Gt(ROSA)26Sor+ mice observed 4 days after tamoxifen administration

mortality/aging
premature death ( J:155109 )
• 10 days after tamoxifen treatment

immune system
increased T cell apoptosis ( J:155109 )
• following tamoxifen treatment, double positive T cells in the thymus exhibit increased apoptosis and necrosis and decreased proliferation compared with T cells from Elavl1tm1Hela homozygotes
thymus hypoplasia ( J:155109 )
• following tamoxifen treatment
decreased leukocyte cell number ( J:155109 )
• 65% 4 days following tamoxifen treatment
decreased double-positive T cell number ( J:155109 )
• following tamoxifen treatment
abnormal myeloid leukocyte morphology ( J:155109 )
• following tamoxifen treatment, myeloid cell numbers are decreased compared to in Elavl1tm1Hela homozygotes
decreased granulocyte number ( J:155109 )
• 4 days following tamoxifen treatment
increased granulocyte number ( J:155109 )
• 2-fold following tamoxifen treatment
spleen hypoplasia ( J:155109 )
• following tamoxifen treatment
abnormal B cell physiology ( J:155109 )
• following tamoxifen treatment, early B cells exhibit increased apoptosis and necrosis and decreased proliferation compared with B cells from Elavl1tm1Hela homozygotes
decreased B cell apoptosis ( J:155109 )
• following tamoxifen treatment, early B cells exhibit increased apoptosis and necrosis and decreased proliferation compared with B cells from Elavl1tm1Hela homozygotes
lymph node hypoplasia ( J:155109 )
• following tamoxifen treatment

hematopoietic system
increased T cell apoptosis ( J:155109 )
• following tamoxifen treatment, double positive T cells in the thymus exhibit increased apoptosis and necrosis and decreased proliferation compared with T cells from Elavl1tm1Hela homozygotes
thymus hypoplasia ( J:155109 )
• following tamoxifen treatment
abnormal definitive hematopoiesis ( J:155109 )
• bone marrow from tamoxifen-treated mice exhibits decreased myeloerythroid colonies on methylcellulose compared with bone marrow from Elavl1tm1Hela homozygotes
decreased common myeloid progenitor cell number ( J:155109 )
• following tamoxifen treatment
decreased bone marrow cell number ( J:155109 )
• following tamoxifen treatment, total bone marrow cell numbers and bone marrow cellularity of immature cells are decreased compared to in Elavl1tm1Hela homozygotes
decreased erythroid progenitor cell number ( J:155109 )
• following tamoxifen treatment
decreased leukocyte cell number ( J:155109 )
• 65% 4 days following tamoxifen treatment
decreased double-positive T cell number ( J:155109 )
• following tamoxifen treatment
abnormal myeloid leukocyte morphology ( J:155109 )
• following tamoxifen treatment, myeloid cell numbers are decreased compared to in Elavl1tm1Hela homozygotes
decreased granulocyte number ( J:155109 )
• 4 days following tamoxifen treatment
increased granulocyte number ( J:155109 )
• 2-fold following tamoxifen treatment
spleen hypoplasia ( J:155109 )
• following tamoxifen treatment
abnormal B cell physiology ( J:155109 )
• following tamoxifen treatment, early B cells exhibit increased apoptosis and necrosis and decreased proliferation compared with B cells from Elavl1tm1Hela homozygotes
decreased B cell apoptosis ( J:155109 )
• following tamoxifen treatment, early B cells exhibit increased apoptosis and necrosis and decreased proliferation compared with B cells from Elavl1tm1Hela homozygotes

digestive/alimentary system
abnormal intestinal epithelium morphology ( J:155109 )
• 2 to 3 days following tamoxifen treatment, mice exhibit massive villus atrophy and disruption of the epithelial architecture unlike Elavl1tm1Hela homozygotes
abnormal intestinal mucosa morphology ( J:155109 )
• disrupted following tamoxifen treatment
abnormal intestinal goblet cell morphology ( J:155109 )
• following tamoxifen treatment, goblet cells are lost unlike in Elavl1tm1Hela homozygotes
abnormal crypts of Lieberkuhn morphology ( J:155109 )
• following tamoxifen treatment, proliferation of crypt progenitor cells is decreased while apoptosis is increased unlike in Elavl1tm1Hela homozygotes
abnormal colon morphology ( J:155109 )
• following tamoxifen treatment, apoptosis of cells in the lamina propria and epithelial cells of the colon is increased compared to in Elavl1tm1Hela homozygotes
small intestinal villus atrophy ( J:155109 )
• 2 to 3 days following tamoxifen treatment, mice exhibit massive villus atrophy unlike Elavl1tm1Hela homozygotes
distended stomach ( J:155109 )
• 2 to 4 days following tamoxifen treatment
intestinal obstruction ( J:155109 )
• 2 to 4 days following tamoxifen treatment the proximal intestine is devoid of food suggesting intestinal blockage

growth/size/body
cachexia ( J:155109 )
• following tamoxifen treatment

cellular
abnormal intestinal goblet cell morphology ( J:155109 )
• following tamoxifen treatment, goblet cells are lost unlike in Elavl1tm1Hela homozygotes
decreased B cell apoptosis ( J:155109 )
• following tamoxifen treatment, early B cells exhibit increased apoptosis and necrosis and decreased proliferation compared with B cells from Elavl1tm1Hela homozygotes
increased T cell apoptosis ( J:155109 )
• following tamoxifen treatment, double positive T cells in the thymus exhibit increased apoptosis and necrosis and decreased proliferation compared with T cells from Elavl1tm1Hela homozygotes
decreased cell proliferation ( J:155109 )
• mouse embryonic fibroblasts treated with 4-hydoxytamoxifen exhibit decreased proliferation compared with similarly treated cells from Elavl1tm1Hela homozygotes

endocrine/exocrine glands
abnormal crypts of Lieberkuhn morphology ( J:155109 )
• following tamoxifen treatment, proliferation of crypt progenitor cells is decreased while apoptosis is increased unlike in Elavl1tm1Hela homozygotes
thymus hypoplasia ( J:155109 )
• following tamoxifen treatment




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
11/12/2024
MGI 6.24 		The Jackson Laboratory